Nabsys, developer of genome-mapping products, has completed its Series B equity funding round

Nabsys 2.0 LLC (“Nabsys”) completed a Series B equity funding round by Hitachi High-Tech Corp (“HHT”) to scale commercial rollout of its current offering and complete the next-generation high-throughput iteration.

Nabsys, based in Providence, RI, United States, develops genome-mapping products designed to analyze whole genome mapping in high definition. The Company’s products use solid-state nano-detectors which can analyze entire genomes, in very large fragments traveling at high velocity, enabling scientists to easily analyze structural variation and assembly of genomes as a way of confirming putative variants. HHT, based in Tokyo, Japan, is engaged in activities in a broad range of business fields, including manufacture and sales of analytical systems, electron microscopes, in vitro diagnostic systems, and semiconductor manufacturing equipment, and providing high value-added solutions in fields of social & industrial infrastructures and mobility.

HHT, based in Tokyo, Japan, is a developer of high-tech solutions by integration of its trading and manufacturing functions.

EC M&A acted as exclusive financial advisor to Nabsys on this transaction.